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Abstract. Decreased activity ofthe guanine nu-
cleotide regulatory protein (N) of the adenylate cyclase
system is present in cell membranes ofsome patients with
pseudohypoparathyrodism (PHP-Ia) whereas others have
normal activity ofN (PHP-Ib). Low N activity in PHP-
Ia results in a decrease in hormone (H)-stimulatable ad-
enylate cyclase in various tissues, which might be due to
decreased ability to form an agonist-specific high affinity
complex composed of H, receptor (R), and N. To test
this hypothesis, we compared f3-adrenergic agonist-specific
binding properties in erythrocyte membranes from five
patients with PHP-Ia (N = 45% of control), five patients
with PHP-Ib (N = 97%), and five control subjects. Com-
petition curves that were generated by increasing con-
centrations ofthe (3-agonist isoproterenol competing with
['251]pindolol were shallow (slope factors < 1) and were
computer fit to a two-state model with corresponding
high and low affinity for the agonist. The agonist com-
petition curves from the PHP-Ia patients were shifted
significantly (P < 0.02) to the right as a result of a sig-
nificant (P < 0.01) decrease in the percent offl-adrenergic
receptors in the high affinity state from 64±22% in PHP-
Ib and 56±5% in controls to 10±8% in PHP-Ia. The
agonist competition curves were computer fit to a "ternary
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complex" model for the two-step reaction: H + R
+ N = HR + N = HRN. The modeling was consistent
with a 60% decrease in the functional concentration of
N, and was in good agreement with the biochemically
determined decrease in erythrocyte N protein activity.
These in vitro findings in erythrocytes taken together
with the recent observations that in vivo isoproterenol-
stimulated adenylate cyclase activity is decreased in pa-
tients with PHP (Carlson, H. E., and A. S. Brickman,
1983, J. Clin. Endocrinol. Metab. 56:1323-1326) are
consistent with the notion that N is a bifunctional protein
interacting with both R and the adenylate cyclase. It may
be that in patients with PHP-Ia a single molecular and
genetic defect accounts for both decreased HRN for-
mation and decreased adenylate cyclase activity, whereas
in PHP-Ib the biochemical lesion(s) appear not to affect
HRN complex formation.
Introduction
Pseudohypoparathyroidism (PHP)' is a rare genetic disorder
characterized by end organ resistance to the effects ofparathyroid
hormone. Albright and colleagues (1) initially reported this dis-
ease and recognized that a particular phenotype, marked by
short stature with shortening of the metacarpals and/or meta-
tarsals, may accompany the biochemical disorder in PHP (1).
Recently, several investigators have recognized that end
1. Abbreviations used in this paper: C, catalytic unit of adenylate cyclase;
EC50, concentration of isoproterenol inhibiting 50% ofradioligand bind-
ing; Gpp(NH)p, guanylyl-imidodiphosphate; H, hormone; N, guanine
nucleotide regulatory protein; PHP, pseudohypoparathyroidism.
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organ resistance to a variety of hormones may occur as part of
the PHP disorder. Thus, dysfunction of thyroid (2-4), gonad-
otropin (5), prolactin (6-8), and glucagon (4) action have been
described as a consequence ofhormone resistance. Very recently,
a blunted plasma cyclic adenosine monophosphate (cAMP) re-
sponse to the infusion of the f3-adrenergic agonist isoproterenol
has been described in patients with PHP (9).
Numerous investigations have been directed at determining
whether a ubiquitous biochemical defect underlies the end organ
resistance to PHP. These investigations have focused on the
hormone (H) receptor-adenylate cyclase complex since it was
first found that patients with PHP do not have a significant rise
in urinary cyclic AMP excretion after the administration of
PTH (10).
The adenylate cyclase-receptor complex consists of at least
three separable plasma membrane components: the hormone
receptor (R), the catalytic unit (C) of adenylate cyclase, and a
guanine nucleotide regulatory protein (G/F orN protein) which
serves to couple the receptor to the catalytic moiety (1 1). Several
lines of evidence have suggested decreased activity of this N
protein in activating adenylate cyclase in various tissues (in-
cluding circulating cells) of some patients with PHP (PHP-Ia)
most of whom had Albright's hereditary osteodystrophy (12-
17). By contrast, phenotypically normal patients, who dem-
onstrate abnormal urinary cAMP excretion in response to para-
thyroid (PTH) infusion, have normal assayable N protein activity
in circulating cells (PHP-Ib).
The f3-adrenergic receptor-N protein-adenylate cyclase com-
plex is the most extensively studied and best understood hor-
monal-adenylate cyclase system (18-20). Previous work has
demonstrated that hormonal agonists promote the coupling of
(-adrenergic receptors with the N protein to form a high affinity
complex (HRN), which is an intermediate in the pathway to
adenylate cyclase activation (21). Guanine nucleotides, which
are required for the hormonal activation of adenylate cyclase,
revert the high affinity state of the receptor to its low affinity
form (HR), concurrent with activation of the adenylate cyclase
enzyme. Quantitation of the percentage of receptors in the high
and low affinity complexes can be accomplished by computer
modeling of agonist competition curves with f3-adrenergic an-
tagonist radioligands (18-19). Cells that either lack the N protein
on a genetic basis (cyc-) (22) or in which there is impaired RN
coupling for any reason show absent or impaired formation of
this high affinity agonist-receptor complex. As a result, such
competition curves are shifted to the right (to higher con-
centration of isoproterenol inhibiting 50% of radioligand
binding [EC50]).
Accordingly, we assessed the ability of(3-adrenergic receptors
ofhuman erythrocytes to form high affinity receptor complexes
in erythrocyte membranes that were derived from five control
subjects, five patients with PHP-Ia (low erythrocyte N protein),
and five patients with PHP-Ib (normal erythrocyte N protein).
This procedure required improvement of methods for detecting
the small number of f3-adrenergic receptors in these cells (23).
The results shed further light both on the nature of the hormone-
responsive adenylate cyclase system and on the pathophysiologic
defects in patients with pseudohypoparathyroidism.
Methods
We studied five patients with pseudohypoparathyroidism type-Ia, five
patients with pseudohypoparathyroidism type-Ib, and five healthy vol-
unteers.
The clinical and laboratory diagnosis of PHP and assessment of the
presence or absence of Albright's hereditary osteodystrophy was made
by Dr. Drezner except for patient A.M. who was evaluated by Dr. Spiegel
(see Table I). The diagnosis of PHP was further confirmed in the patients
by measurement of the urinary cAMP response to PTH infusion (10),
which in all cases was <20 ,gmol cAMP/g creatinine in the urine. In
addition, all patients demonstrated a reduced phosphaturic response to
PTH and elevated tubular maximum for reabsorption of phosphate.
Each patient was initially evaluated while he was untreated and hy-
pocalcemic. The present studies were performed after long-term treatment
with vitamin D and/or calcium supplementation in each patient and
with maintenance of normocalcemia.
At the time of the study, PTH hormone levels were determined by
three different radioimmunoassays, which have been previously described
and validated (24-26). "PTH assay 1" is a carboxy-terminal PTH assay
performed at the Mayo Clinic (24). "PTH assay 2" is performed at
Duke University and is also a carboxy-terminal PTH assay (25). "PTH
assay 3" was performed on one patient (A.M.) and is a mid-region
(amino acids 44-68) assay (26).
Human erythrocyte membrane preparation. After obtaining informed
consent, we obtained 200 ml of whole blood via venipuncture. A 45-
ml aliquot of this whole blood was collected into 5 ml of acid-citrate-
dextrose anticoagulant and immediately placed on ice but not frozen.
Erythrocyte membranes were prepared within 24 h of venipuncture for
determination ofN protein activity (13). N protein was assayed according
to the reconstitution assay described by Kaslow et al. (27) but was
modified by incubating the erythrocyte membrane extracts and cyc-
membranes for 20 min at 30'C in the presence of adenylate cyclase
assay mixture before the addition of [32P]ATP and the performance of
the assay.
We anticoagulated the remaining 155 ml of whole blood by using
U. S. Pharmacopoeia sodium beef lung heparin (The Upjohn Co., Ka-
lamazoo, MI) (1,000 U ofheparin per 49 ml ofwhole blood) and prepared
erythrocyte ,B-adrenergic receptor-containing membranes. The eryth-
rocytes were sedimented by the addition of 10 ml of 3% Dextran (Dextran
T-500, Pharmacia Fine Chemicals, Piscataway, NJ) in normal saline to
25 ml of whole blood and left undisturbed for 20 min. The supernatant
layer, which contained the plasma and most ofthe leukocytes and plate-
lets, was discarded and 50 ml of erythrocytes was used for subsequent
steps. These erythrocytes were washed three times with normal saline
by centrifugation at 1,600 g and both the supernatant and small buffy
coat layer on top of the erythrocyte layer were aspirated and discarded.
We used 25 ml of the total volume of washed erythrocytes for the
erythrocyte ,B-adrenergic receptor assays.
I ml ofthe washed erythrocyte preparation was used for determination
of the erythrocyte count and to assess the homogeneity of the erythrocyte
preparation. Blood counts were made by use of an ELT-8/d.s. (Ortho
Instruments, Westwood, MA) cell counter and by direct quantitative
examination of a smear of the erythrocyte preparation for the presence
of platelet and white cell contaminants.
Since we observed that the level of erythrocyte fl-adrenergic receptor
binding was very low, we sought to rigorously exclude the possibility
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Table I. Patient Population Characteristics
Serum Serum Serum Serum
Patient Age Sex calcium* phosphorus* PTH-assay I t PTH-assay 2*§ N Protein"l*
mg/dl mg/dl ueq/ml ng/ml % of control
PHP-Ia patients
G.W. 33 F 8.7 4.4 85 1.7 56±9
L.H. 32 M 9.5 3.9 0.73 43±9
M.W. 7 M 8.9 4.9 3.14 62±6
J.P. 22 F 9.5 3.8 1.70 41±7
A.M.+ 28 F 8.8+ 5.0+ 22±9
PHP-Ib patients
K.R. 14 M 9.2 3.4 - 0.87 96±21
B.R. 13 F 9.1 5.4 110 2.34 84±13
S.R. 34 F 9.1 3.7 51 2.26 100±16
B.M. 49 F 9.6 3.7 - 1.1 97±11
R.J. 29 F 9.5 4.1 65 110±17
Normal values 8.8-10.2 2.5-4.5 <70 <1.5 100
* Measured while on vitamin D and/or calcium replacement. f Mayo Clinic assay (see Methods and reference 24). § Duke University assay
(see Methods and reference 25). 1l N protein assay (see Methods and reference 27). ¶ All assays for patient A.M. were performed at the Na-
tional Institutes of Health (NIH): PTH level for A.M. = 63 (nl = 2-50 fmol * eq/ml, see Methods and reference 26); normal NIH values
(serum): calcium = 9.0-10.6; phosphorus = 2.4-4.4.
that the observed binding was associated with membranes derived from
other cell types. We found a low level of leukocyte and platelet con-
tamination in the erythrocyte layer before lysis of cells for membrane
preparation. An average of250±130 leukocytes and 5,500±3,000 platelets
per cubic millimeter were present in control preparations; 100±50 leu-
kocytes and 5,500±2,900 platelets, in PHP-Ia patients; and 100±170
leukocytes and 5,200±3,200 platelets, in PHP-Ib preparations. Thus,
the level of leukocytes and platelets present in the erythrocyte preparation
was consistently <5% ofthe level found in the whole blood ofthe donor.
25 ml of washed erythrocytes was lysed by the addition of 225 ml
of ice-cold distilled water and allowed to sit undisturbed for 10 min on
ice. Subsequently, the lysed erythrocytes were gently homogenized on
ice in a 40-ml Dounce homogenizer. An equal volume of cold membrane
buffer (75 mM Tris-HCI buffer, pH 7.5, containing 25 mM MgCl2 and
1.5 mM EDTA) was added to the homogenate and centrifuged at 40,000
g for 10 min at 40C. The hemoglobin-containing supernatant was dis-
carded and the membrane pellet was then washed three times with
membrane buffer by centrifugation at 40,000 g for 10 min at 4VC. The
resulting white or light pink pellet was then resuspended to a volume
of 50 ml with membrane buffer and used for the f3-adrenergic receptor
assay. This membrane preparation was also assayed for protein con-
centration according to the method of Lowry et al. (28).
Human erythrocyte membrane 0-adrenergic receptor assay. We per-
formed competition and saturation binding isotherms on membranes
from all subjects by using standard radioligand binding techniques (29).
['251I]Iodopindolol was prepared from (-)pindolol by radioiodination
with chloramine T and ['251I]NaI (30). The product was completely re-
solved from uniodinated pindolol and was therefore assumed to have
theoretical specific activity of 2,200 Ci/mmol.
Saturation binding isotherms were constructed using 0.4 ml of the
erythrocyte membrane preparation and [1251]pindolol concentrations
from 25 to 800 pM in a total assay volume of0.6 ml. IO-'M isoproterenol
that was prepared in membrane buffer containing l0-3 M sodium as-
corbate (Sigma Chemical Co., St. Louis, MO) was used to define non-
specific binding. Assays were incubated at 370C for 30 min and were
performed in duplicate. Bound ['25Ipindolol was separated from unbound
[125I]pindolol by filtering the membranes over Whatman GF/C glass
fiber filters and then washing with 25 ml of cold membrane buffer. The
filters were then counted in an Auto Gamma 800 gamma counter (Pack-
ard Instrument Co., Inc., Downers Grove, IL).
Competition binding isotherms were constructed by using isopro-
terenol concentrations in the assay from 10-9 to 10-3 M in competition
with 200 pM ['25I]pindolol for binding to erythrocyte membrane f3-
adrenergic receptors. The incubation and washing conditions were as
described for the saturation binding isotherms and the total volume of
the assay was also 0.6 ml (100 Ml of isoproterenol or buffer, 100 ul of
['251I]pindolol and 400 Ml ofmembranes) and were performed in duplicate.
Competition binding isotherms were performed in parallel in the presence
and absence of l0-4 M guanylyl-imidodiphosphate (Gpp(NH)p) (Boeh-
ringer-Mannheim Biochemicals, Indianapolis, IN).
We attempted to measure adenylate cyclase in these human eryth-
rocyte membranes according to the method of Salomon et al. (31).
Despite the addition of theophylline, forskolin, and the use of various
incubation conditions and temperatures, no fluoride- or isoproterenol-
stimulatable adenylate cyclase could be measured.
Data analysis. Data from the saturation and competition binding
assays were analyzed and modeled by computer techniques as previously
described (18, 19, 32). Competition curves were fit with a four-parameter
logistic equation, which provided the slope factor and EC50 for each
curve (32). Next, the curves were modeled according to the law of mass
action to provide the best fit to a model, assuming a single state of the
receptor or to a model assuming two states (high and low affinity) of
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the receptor. A two-affinity state model was accepted only ifit was shown
to significantly (P < 0.05) improve the fit over a single-affinity state
model. This program provided the affinity constants and proportions
of the receptors in the high affinity or low affinity state for isoproterenol
(9). This program was also used to fit the saturation binding isotherms
for [125I]pindolol and invariably such data were adequately modeled to
a one-site fit.
When modeling the competition curves according to the law ofmass
action, the following approach was taken. The data from each subject
were first modeled individually and was then averaged with data from
other subjects in three different ways. The first method was to plot every
data point from each of the five people in each donor group (normal
controls, PHP-Ia, PHP-Ib) and then have the computer fit the best curve
to all the data points for each group of patients. The second method
was to average the binding data from each group of patients at a given
concentration ofcompeting isoproterenol and to generate a single com-
petition binding isotherm from the patient data within a donor group.
The third technique was to average the parameter values obtained from
each patient's data individually within each of the three donor groups.
These three methods of averaging the data within a group of donors
yielded results that were virtually identical. The data and curves obtained
by the second method above are presented in this paper.
As a final approach, the isoproterenol competition curves from the
three subject groups were analyzed by using the "ternary complex"
model, which we have previously proposed and validated to account
for ligand interactions with plasma membrane (l-adrenergic receptors.
The model is (19):
K
H + R + N HR + N
IrM ItL
K'
H + RN = HRN
K, K', L, and M represent the equilibrium constants for the various
reactions. The curve fitter based on this model provides estimates for
the association constant (K) of isoproterenol with the free form of the
receptor (R) and the equilibrium constant (L) for the isoproterenol-
promoted coupling of the receptor with a guanine nucleotide binding
protein (N) as well as estimates of the relative concentrations of R and
N in the system.
The assumptions used for this modeling were the following. (a)
There was negligible interaction or "precoupling" of R with N in the
absence of any ligand. In essence this sets the parameter M = 0. This
assumption was based on ititial results that indicated that including a
precoupled form of the receptor (RN) in the modeling did not improve
the accuracy with which the data could be fit. (b) The K& for the ra-
dioligand ['25I]pindolol was the same for controls and PHP-Ia and PHP-
Ib patients and was determined by the analysis of ['25I]pindolol saturation
curves with the mass action model (see Fig. 2). (c) The radioligand had
no effect on the equilibrium between the free and coupled forms of the
receptor so that it had identical affinity for R and RN. This was based
on the finding that ['25I]pindolol saturation curves were always adequately
fit by a one-state model. (d) There was no difference in the properties
ofisoproterenol interactions with the receptors between the three subject
groups, i.e., that the values of L and K were the same for all three
groups. That the value ofKis the same in the different groups is supported
by the finding that the agonist competition curves in the presence of
the guanine nucleotide analog Gpp(NH)p were all superimposable. It
has previously been demonstrated that guanine nucleotides convert all
high affinity state receptors to low affinity state receptors and hence the
affinity constant measured under these conditions should represent K
(18, 19). Although the parameter L might have varied between the
groups, it was set constant since (a) excellent fits to the data could be
obtained when L values were shared among the three groups and (b)
the major hypothesis that we wished to test with the ternary complex
modeling was whether the binding data were consistent with the bio-
chemically established decrease in the concentration of N in the mem-
branes.
Statistical comparisons. With each ofthe three types of curve-fitting
programs used, parameter values derived from the different patient groups
were compared by constraining the computer fit competition curves
from the different groups to share common values (e.g., EC~, slope
factor, Kd, etc.) and testing for worsening of the fit while keeping other
values constant. Parameters werejudged as significantly different ifsharing
of these parameters led to a significant (P < 0.05) worsening of the fit
compared with that obtained when parameters were determined inde-
pendently for each group (19). In other cases, parameters from the
differing groups were compared by a one-way analysis of variance.
Results
Characteristics ofligand binding to the human erythrocyte mem-
brane beta-adrenergic receptor. As shown in Fig. 1, the binding
of 200 pM ['25I]pindolol to the f3-adrenergic receptor ofhuman
erythrocyte membranes reaches equilibrium by 30 min at 370C
(Fig. 1). This interaction appears to be stable for >60 min at
this temperature without significant degradation of the assayable
receptor. The dissociation of [1251]pindolol from the receptor
has a t1/2 of 12 min at 370C.
Erythrocyte membrane f3-adrenergic receptor binding of
[125I]pindolol has the typical specificity and stereospecificity of
a f32-adrenergic receptor (Fig. 2 A-C).
A typical saturation binding isotherm ofthe erythrocyte 2-
adrenergic receptor ofa normal subject for [1251]pindolol is shown
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Figure 1. Kinetics of [125I1 pindolol binding to human erythrocyte #2-
adrenergic receptors. Human erythrocyte 12-adrenergic receptors were
prepared from healthy volunteer subjects as described in the text and
were incubated with 200 pM [125Ilpindolol at 370C for varying peri-
ods of time. At various times, as indicated by the abcissa, aliquots
were taken and specific binding was assessed by using the filtration
technique described in the text. In a parallel experiment, the off-ki-
netics were studied by the addition of 10-4 M isoproterenol to com-
pete with the radiolabeled pindolol. Aliquots of the incubation mix-
ture were then sampled at the times shown.
1338 Heinsimer et al.
Downloaded on September 24, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/111336
00 100
z
c) 80
CCIn
12 II 10 9 8 7 6 5
- LOG [AGONIST] M
3.0
2.5
z
0m
-J
0
-j
0
z
E.
In
2.0
0.54 3 2
C
-j
0
J
0
a
z
L--
0
O
z
z
m
x
n
0
0
0
z
a.
LA.
0
xD
z
z
"IO
80 _
a 5-(+) PRO
60 ICI PHENTO\118.551 4
40 (+/-)ATEN-
(-PRO
20 ~ ~ ~20
12 11 10 9 8 7 6 5 4 3 2
-LOG [ANTAGONIST] M
I0(
8(
6(
4(
21
9 8 7 6 5 4
-LOG [ISOPROTERENOL] M
3 2
Figure 2. #2-Adrenergic specificity and stereospecificity of adrenergic
binding of human erythrocyte membranes. Competition binding iso-
therms were performed at 370C for 30 min by using 400 Ml of hu-
man erythrocyte membranes prepared as described in the text, 100 JA
of ['25I]pindolol, and 100 of unlabeled agonist or antagonist. A
shows the mean results of three competition experiments (determined
in duplicate) in which increasing concentrations of (-)isoproterenol,
(-)epinephrine, and (-)norepinephrine compete with ['25I]pindolol
for binding to the human erythrocyte membranes. In B, increasing
concentrations of the antagonists (-)propranolol, ICI-1 18, 551,
(+)propranolol, (±)atenolol, and phentolamine are allowed to com-
pete with ['25I]pindolol for binding to human erythrocyte mem-
branes. In C (-)isoproterenol and (+)isoproterenol are shown in
competition with ['25I]pindolol for binding to human erythrocyte
membranes.
U0 120 240 360
[1251] PINDOLOL (pM)
480 600
Figure 3. Saturation binding isotherm of the erythrocyte 2-adrener-
gic receptor of a normal subject for ['25I]pindolol. Human erythro-
cyte membranes were prepared as described in the text and were as-
sayed for fl-adrenergic binding by using the radioligand ['25I]pindolol.
Saturation binding isotherms were constructed with 400 y1 of the
erythrocyte membrane preparation and ['25Ipindolol concentrations
from 25 to 800 pM in a total assay volume of 0.6 ml. Incubation
was carried out at 370C for 30 min. The nonspecific binding was de-
fined as binding of ['25I]pindolol in the presence of 10-' M isoproter-
enol. Specific ,B2-adrenergic binding is the total binding as shown by
the solid line minus the nonspecific binding as shown by the dashed
line. The solid line represents the computer-generated best-fit curve
for a single class of sites.
in Fig. 3. The specific binding was defined as the difference
between ['25I]pindolol bound in the presence or absence of IO-'
M (-)isoproterenol. Such saturation curves were adequately
modeled to a single site fit, which indicated interactions of the
radioligand with an homogeneous population ofreceptor binding
sites of uniform affinity.
The average (n = 5 subjects each) erythrocyte ,3-adrenergic
receptor concentrations and dissociation constants (Kd) for
[1251I]pindolol (Table II) did not differ between the groups. The
density of sites was extremely low and presumably accounts for
difficulties of others in demonstrating these binding sites in the
past.
Since fl-adrenergic receptors are known to exist on leukocytes
(33) and platelets (34), we sought to exclude these cell types as
the source of the ,3-adrenergic receptor activity in our prepa-
rations. We found that when the erythrocyte preparations were
made entirely leukocyte- and platelet-free by cell elutnation that
the erythrocyte 32-adrenergic receptor binding was unchanged,
i.e., Kd and receptor density were the same as in standard prep-
arations containing a small amount (<5% ofinitial whole blood)
of white cell or platelet contaminants (data not shown). More-
over, when platelets and leukocytes were deliberately left in the
preparation and membranes were prepared, the f3-adrenergic
binding properties and total 032-adrenergic receptor concentration
were unchanged (data not shown).
1339 Impaired 30-Complex Fomwion in Pseudohypoparathyroidism
So f~~N\--* A
\'
0-- (-)ISO
n--a (-)EPI
NE IP
/ * * ~~~Total Binding
/ O---O Binding in Presence of10-4 M H-) Isoproterenol
J -0-a
D.
1.5
D.
I.0
I
Downloaded on September 24, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/111336
Table I. Erythrocyte #rAdrenergic Receptor Binding Data
P values for PHP-Ia
Control PHP-lb PHP-1a patients vs. control
Saturation binding isotherm
Receptor concentration (fmol/mg protein) 2.1±0.6 2.0±0.6 2.6±1.5 NS
Kd for ['25I]pindolol (pM) 141±69 153±44 177±119 NS
Competition curve data
Slope factor
Gpp(NH)p absent 0.6±0.1 0.8±0.1 0.9±0.1 0.05
Gpp(NH)p present i.1±0.2 1.0±0.1 1.0±0.2 NS
EC30
Gpp(NH)p absent (M) 4.7±1.5 X 10-7 4.9±2.0 X 10-7 1.2±0.2 X 10-6 <0.001
Gpp(NH)p present (M) 2.0±0.5 X 10-6 1.9±0.6 X 10-6 2.5±0.1 X 10-6 NS
% Receptor in high affinity form
Gpp(NH)p Absent 56.2±5.4 64.0±21.5 10.2±8.4t <0.001
* All values are not significantly different from control (P > 0.05). * In this case a two-site fit was not significantly better than a one-site fit
since so little of the high affinity state of the receptor was formed. However, for purposes of comparison this value was used rather than a value
of 0% (the value implied by a one site fit).
All of these lines of evidence indicate that platelet or leu-
kocyte binding did not account for the observed binding in these
preparations but rather that a low level of receptors is, in fact,
present on erythrocytes.
Comparison of isoproterenol competition curves between
control subjects and PHP patients. Isoproterenol competition
curves in the presence or absence of Gpp(NH)P, representing
the averaged, normalized data for each of five control, PHP-Ia
and PHP-Ib subjects, are shown in Fig. 4 and the various pa-
rameters derived from these curves are summarized in Table
II. The competition curves for control subjects and patients with
PHP-Ib are virtually identical. The average EC50 for controls
was 4.7 X 10-7 M while that for patients with PHP-Ib was 4.9
X l0-7 M without Gpp(NH)p (P = NS). In the presence of
Gpp(NH)p these values were 2.0 X 10-6 M and 1.9 X 10-6 M
for controls and PHP-Ib patients, respectively (P = NS). In the
absence ofGpp(NH)p the slope factor ofthe isoproterenol com-
petition curve derived from subjects with PHP-Ib is not sig-
nificantly steeper than for control subjects (P = 0.48); however
both competition curves were steep with slope factors that ap-
proximated 1.0 in the presence of Gpp(NH)p. Similarly, both
the PHP-Ib and control subjects have -60% of their #2-adren-
ergic receptor population in the high affinity form in the absence
of Gpp(NH)p. The percentage of receptors in the high affinity
state was 64% for the PHP-Ib patients and 56% for controls but
this difference was not statistically different (P > 0.5).
OJ * Figure 4. Isoproterenol competition curves00A I ~.~* in the presence and absence of10-4 M
80a_.9n+ \ ISO + 10-4 M _IS + 10-4 M Gpp(NH)p are compared for control subjects
e LA Gpp(NH)p added \ Gpp(NH)p added against PHP-Ib and PHP-Ia patients. Isopro-terenol competition curves were performed
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z 40 branes derived from human erythrocytes. In
Z \ \ \'\ the left-hand panel, data for control subjects
<20_ are shown by oand*in the absence andx Control 0,0 Control presence of Gpp(NH)p, respectively. The isos 0 *A^PHP- lb 0__9 PHP-la proterenol competition curves of the PHP-Ib0 patients are shown in the absence of9 8 7 6 5 4 9 8 7 6 5 4 3 Gpp(NH)p (A) or in the presence of 10-4 M
- LOG [ISOPROTERENOL] M Gpp(NH)p (A). In the right-hand panel the
same control data are shown again by the 0
and * in the absence or presence of 10- Gpp(NH)p, respectively. The competition data for the PHP-Ia patients are shown in the absence (0) or
presence (m) of 10-' M Gpp(NH)p. All data represent the mean of duplicate determinations from five patients or controls. The lines represent
the computer-generated best fits according to the law of mass action (see Methods).
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In contrast, visual inspection ofthe curves in Fig. 4 illustrates
that the competition curve representing data from patients with
PHP-Ia is different from that ofsubjects with PHP-Ib or controls
in the absence of Gpp(NH)p. The curve for the PHP-Ia group
is shifted to the right with an EC50 of 1.2±0.2 X 10-6 M, which
is significantly different than the curve for the PHP-Ib or control
groups (P < 0.001).
The rightward shift and steepness ofthis curve are compatible
with decreased formation of the high affinity receptor complex
(19), which is presumably a reflection of decreased formation
ofHRN (18, 19). As shown in Table II, only 10% ofthe receptors
are found to be in the high affinity form by computer modeling.
Thus, a significantly lower percentage of the 032-adrenergic re-
ceptors are able to form a high affinity complex in the eryth-
rocytes of PHP-Ia patients than in the controls (P < 0.01) or
the PHP-Ib patients (P < 0.01). Importantly, the dissociation
constants for the isoproterenol competition curves in the absence
of Gpp(NH)p were not statistically different between control
and PHP-Ib and PHP-Ia patients.
To assess if a change in the stoichiometric ratio of N/R
could explain the alterations in isoproterenol competition curves
documented in Fig. 4 and Table II, we simultaneously analyzed
the curves obtained for all three groups in the absence of
Gpp(NH)p, together with a common competition curve in the
presence of Gpp(NH)p as described in Methods using the "ter-
nary complex" curve fitter. The results of the analysis indicated
that the data from PHP-Ia subjects were best described as having
a ratio of N to R that was - 40% of that determined for the
other two subject groups (concentrations of N = 0.6±0.1 pM
for PHP-Ia data vs. 1.5±0.1 pM for control and PHP-Ib data;
see Table III). These results are consistent with a 60% loss in
functional N from PHP-Ia subjects, as compared with the other
groups.
N protein determinations. Erythrocyte N protein activity
was 103±7% of normal (range = 92-109%) for controls, 97±9%
(range = 84-1 10%) for the PHP-Ib patients, and 45±15% (range
= 22-62%) for the PHP-Ia patients (Table III) as determined
by the reconstitution assay discussed in Methods.
Discussion
The ability to assess 3-adrenergic receptors and f(-adrenergic
receptor-N protein interactions in erythrocyte membranes from
PHP patients and controls has afforded us a unique opportunity
to probe the status ofthese components ofthe adenylate cyclase
system in a human tissue under normal and pathophysiologic
circumstances. In the present study we have shown that in pa-
tients in whom erythrocyte N protein is diminished (PHP-Ia),
the interaction of the agonist isoproterenol with the ,B-adrenergic
receptors is altered. We demonstrated an impaired ability of
the receptors to form an agonist-promoted high affinity state as
assessed by nonlinear least-squares curve fitting procedures. Such
a reduction in high affinity agonist binding is highly suggestive
of a reduction in the amount of the ternary complex HRN
formed. This was directly demonstrated by computer modeling
of isoproterenol competition curves with the ternary complex
model (18). This modeling suggested a - 60% reduction in the
functional N pool in the PHP-Ia patients. Although the results
of the computer modeling do not categorically exclude a re-
duction in the L value for HRN complex formation, the cal-
culated reduction in N protein concentration is consistent with
the reduction in N protein activity observed in the biochemical
assays of N.
In other situations where N is genetically deficient, such as
the cyc- variant of S49 lymphoma cells (22), or in situations
where there is uncoupling of R from N such as desensitization
(35), hypothyroidism (36), or hypoadrenalism (37), there is a
reduction in the agonist-specific high affinity binding component
that is demonstrated by a right-shifted and steepened agonist
competition curve. This was precisely the situation documented
in this study for the competition curves of the PHP-Ia patients.
It is reasonably well established that formation of the HRN
complex is a necessary prerequisite for cAMP formation (20).
Thus, assuming that the results in erythrocytes are relevant to
the situation in other tissues, it is possible that the decreased
ability to form the HRN complex contributes to the decreased
PTH, thyroid-stimulating hormone and other N protein-me-
Table III. Parameter Estimates from Data Analysis by using the Ternary Complex Model and Percentage
Estimates ofN-Protein Activity
Group KNsoLiso R. N, % N % N protein activity
pM pM pM pM
Control 1.2±0.07 X 106 0.14±0.02 2.4 1.5±0.1 100 103±7
PHP-Ib 1.2±0.07 X 106 0.14±0.02 2.4 1.5±0.1 100 97±9*
PHP-Ia 1.2±0.07 X 106 0.14±0.02 2.4 0.6±0.1§ 40 45±15t
Kiso, dissociation constant for isoproterenol with free form of receptor (R); Llso, equilibrium dissociation constant for isoproterenol-promoted
coupling of R with N; Rt, estimate of total receptor concentration; N., total N concentration; % N, percentage of estimated N with respect to
control values; % N protein activity, percentage of NIH laboratory controls (see Methods). * Not significantly different from control values.
t Significantly different from control values (P < 0.001). § P < 0.001 compared with fit where N for PHP-Ia is shared with that for other
groups.
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diated hormonal responses observed in patients with PHP-Ia.
However, the present data do not permit us to assess the extent
to which such a lesion, as opposed to decreased ability ofN to
activate C, determines the ultimately reduced generation ofcyclic
AMP in response to hormones in these patients. Again, as in
other conditions ofaltered receptor coupling, computer modeling
of agonist competition curves from PHP-Ia patients provided
a direct quantitative estimation of the characteristics of the
pathological changes in RN coupling.
Since patients with PHP-Ib have the same characteristics of
agonist receptor interaction as controls, it is likely that the defect
in this entity does not involve the coupling of H, R, and N.
Thus, the site of the biochemical lesion in patients with PHP-
Ib remains to be determined.
Although we were unable to measure adenylate cyclase re-
sponsiveness to 3-agonist stimulation in these human erythrocyte
membranes, a recent study (9) sheds important light on this
question. Seven patients with PHP (three with PHP-Ia and four
with PHP-Ib) were found to have a significantly blunted plasma
cAMP response to isoproterenol infusion as compared with nor-
mal subjects. However, the PHP-lb patients' cAMP response
to isoproterenol infusion was blunted to an even greater degree
than the PHP-Ia patients. Thus, in vivo, it appears that some
component(s) of the adenylate cyclase-coupled fl-adrenergic re-
ceptor system is abnormal in both PHP-Ia and PHP-Ib patients.
However, the results of our work demonstrate that in vitro,
agonist-induced receptor-N protein coupling is normal in eryth-
rocytes from PHP-lb patients. Thus, it is likely that a molecular
understanding of the decreased cAMP formation in PHP-Ib
patients will have to await development of further techniques
for the investigation of this problem.
A major hypothesis that has been tested by the present work
is whether the defect in the functional pool of N molecules
present in the cell membranes of patients with PHP-Ia would
be discerned in the patterns of agonist binding to 13-adrenergic
receptors. As noted, this hypothesis was confirmed by our ob-
servations. These data are consistent with the notion that in
PHP-Ia patients a quantitative defect in a single gene product
(i.e., N or some component thereof) might be responsible both
for the ligand binding abnormalities demonstrated in this work
and for decreased adenylate cyclase activation demonstrated in
other work (12, 17). Our findings further support the idea of a
single bifunctional N protein that interacts with both R and C.
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